Conclusions & Recommendations
14.8.1 - Ethiopia - Gambella
Conclusion/Recommendation:
Once refugee camp mapping data are available, the Regional Health Bureau and Federal Ministry of Health are encourages to submit a mid-year request, if warranted and funding is available, to enable delivery of treatments in 2016.
Action:
A presentation on the surveys will be made at TEC 15.
TEC 14
2016
Africa - East
Ethiopia
special populations, Zithromax® donation criteria
14.9.1 - Ethiopia - Oromia
Conclusion/Recommendation:
A survey needs to be conducted in Gechi before additional drug requests can be considered.
Action:
Discussions have been conducted with the implementing partner, FHF, but a commitment to conduct the surveys has not been made.
TEC 14
2016
Africa - East
Ethiopia
evaluation units, Zithromax® donation criteria
12.1.1 - Mitigation of Zithromax® Production Delays
Conclusion/Recommendation:
TEC recommends that ITI continue to apply the measures put into place following the April eTEC meeting to mitigate ongoing Zithromax® production delays in 2016, including:
• Strictly adhere to the ‘Green Light’ check list when shipping: Multiple just-in-time shipments by air, subtracting in-country inventory and cancelled treatments
• Send 95% of Zithromax® allocation: Minimize Zithromax® surplus after each district MDA by shipping sufficient Zithromax® to achieve 95% coverage of eligible population
• Postpone 2015 treatments for districts still pending funding: Defer distribution to late 2015 or early 2016, depending on availability of Zithromax® and funding
• Delay West Amhara distribution for 2015: Delay West Amhara treatments currently scheduled for November 2015 to Q1 2016
Action:
All recommended measures have been implemented. These interim measures were communicated to countries immediately following the April eTEC, and the countries have all been remarkably accepting. The Carter Center was thanked for their willingness to postpone treatments until early 2016, making it possible to be on target to ship all other country Zithromax® needs by year-end 2015. Flexibility from The Carter Center is appreciated, but we may still be able to ship in 2015 for their 2016 Q1 treatments.
TEC 12
2015
supply chain, Zithromax® donation criteria
12.1.2 - Mitigation of Zithromax® Production Delays
Conclusion/Recommendation:
TEC recommends that ITI continue to practice transparency and work with the countries, donors, and implementing partners to carefully plan Zithromax® shipping schedules in order to minimize disruption to the overall Global Programme.
Action:
ITI’s supply chain and program teams have worked closely to minimize the impact of the shipping delays on countries, taking into account funding patterns, seasonal changes, and other potential challenges. ITI continues to provide ongoing updates to National Program Coordinators, predicting shipment dates and informing them of any delays. Donors and implementing partners have also been given full reports of country shipping status as requested.
TEC 12
2015
12.10.1 - TEC Approvals for 2016: Guinea-Bissau
Conclusion/Recommendation:
TEC recommends that an impact assessment be funded and implemented in Cacheu as soon as possible to enable the submission of a mid-term request at TEC 13 if results warrant.
Action:
Sightsavers are finalizing funding for the impact assessment.
TEC 12
2015
12.11.1 - TEC Approvals for 2016: Mali
Conclusion/Recommendation:
TEC recommends that if the results of the impact assessments are available and warrant additional treatment, a mid-term request be presented at TEC 13 for Ansongo, Bourem, and Gao in Gao region; Kayes and Nioro in Kayes region; and Niafunké in Tombouctou.
Action:
The results of the impact assessment did not warrant a new request for Kayes and Nioro (0.51% TF and 0.22% TF, respectively). Impact assessments will be conducted as soon as security permits in Ansongo, Bourem, and Gao. Therefore, no mid-term request will be presented at TEC 13 for these districts.
TEC 12
2015
12.12.1 - TEC Approvals for 2016: Mauritania
Conclusion/Recommendation:
TEC recommends that Mauritania conduct their impact assessments as soon as possible, seeking assistance from WHO and ITI.
Action:
ITI is currently working with MOH, WHO and GTMP to develop a protocol and budget for a proposal prepared by the ICTC and submitted to the END Fund to request support for impact assessments in 2016.
TEC 12
2015
12.13.1 - TEC Approvals for 2016: Niger
Conclusion/Recommendation:
TEC has approved a request of 150,000 Zithromax® treatments to treat refugees from Nigeria in the border areas in Diffa.
Action:
The refugee population was added to Diffa’s population and communicated to the country.
TEC 12
2015
12.14.1 - TEC Approvals for 2016: Nigeria
Conclusion/Recommendation:
TEC recommends a follow-up visit by ITI-HQ staff to conduct a supply chain spot check.
Action:
ITI is planning to make a supportive observational visit at the time of the upcoming MDAs and will conduct a supply chain spot check, taking a collaborative approach to address any shortfalls.
TEC 12
2015
12.14.2 - TEC Approvals for 2016: Nigeria
Conclusion/Recommendation:
The national program is encouraged to submit a mid-term Zithromax® request for surgery to be reviewed at TEC 13.
Action:
Mid-term Zithromax® request for surgery has been submitted and will be reviewed during TEC 13.
TEC 12
2015